Pfizer (NYSE:PFE) increased the lower end of its full-year revenue guidance after reporting second-quarter 2026 results that exceeded Wall Street expectations, supported by robust sales of its blood thinner Eliquis.
The pharmaceutical company also reaffirmed its earnings outlook for the year, while its shares moved higher in U.S. pre-market trading following the announcement.
Revenue and Earnings Beat Expectations
Pfizer generated second-quarter revenue of $15.03 billion, comfortably above the Bloomberg consensus estimate of $14.41 billion.
Adjusted earnings came in at $0.77 per share, exceeding analysts’ expectations of $0.68, according to LSEG data cited by Reuters.
The stronger-than-expected performance was largely driven by continued demand for Eliquis.
Eliquis Continues to Support Growth
Worldwide sales of Eliquis increased 21% year over year to $2.425 billion during the quarter.
Higher pricing in the United States helped offset growing competition from generic alternatives, allowing the anticoagulant to remain one of Pfizer’s most important products.
Eliquis accounted for roughly one-sixth of the company’s total revenue during the June quarter.
Company Raises Full-Year Revenue Guidance
Pfizer increased the lower end of its 2026 revenue forecast by $1 billion.
The company now expects full-year revenue to range between $60.5 billion and $62.5 billion, compared with its previous guidance of $59.5 billion to $62.5 billion.
The drugmaker maintained its adjusted diluted earnings per share guidance of $2.80 to $3.00.
That forecast includes a negative impact of $0.10 per share related to the company’s global licensing and collaboration agreement with China’s Innovent Biologics.
Management Expresses Confidence
Incoming Interim Chief Financial Officer Cecile Guegan said the updated outlook reflects continued confidence in the company’s performance.
“The updated guidance reflects the continued strength of and confidence in our business.”
Focus Remains on Future Growth
Following the sharp decline in COVID-related product demand, Pfizer has continued to strengthen its pipeline through acquisitions and new product development.
The company’s $10 billion acquisition of Metsera in November is widely viewed as part of its strategy to establish a stronger position in the rapidly expanding weight-loss drug market, where competitors such as Eli Lilly and Novo Nordisk currently dominate.
Pfizer stock price
